Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study

Publikation: Bidrag til tidsskriftLetterForskningfagfællebedømt

Standard

Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis : A retrospective multicenter study. / Schwensen, J F; Clemmensen, A; Sand, C; Gniadecki, R; Skov, L; Zachariae, C; Iversen, L; Rasmussen, M; Thomsen, S F.

I: Dermatologic Therapy, Bind 30, Nr. 6, e12550, 11.2017.

Publikation: Bidrag til tidsskriftLetterForskningfagfællebedømt

Harvard

Schwensen, JF, Clemmensen, A, Sand, C, Gniadecki, R, Skov, L, Zachariae, C, Iversen, L, Rasmussen, M & Thomsen, SF 2017, 'Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study', Dermatologic Therapy, bind 30, nr. 6, e12550. https://doi.org/10.1111/dth.12550

APA

Schwensen, J. F., Clemmensen, A., Sand, C., Gniadecki, R., Skov, L., Zachariae, C., Iversen, L., Rasmussen, M., & Thomsen, S. F. (2017). Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study. Dermatologic Therapy, 30(6), [e12550]. https://doi.org/10.1111/dth.12550

Vancouver

Schwensen JF, Clemmensen A, Sand C, Gniadecki R, Skov L, Zachariae C o.a. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study. Dermatologic Therapy. 2017 nov;30(6). e12550. https://doi.org/10.1111/dth.12550

Author

Schwensen, J F ; Clemmensen, A ; Sand, C ; Gniadecki, R ; Skov, L ; Zachariae, C ; Iversen, L ; Rasmussen, M ; Thomsen, S F. / Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis : A retrospective multicenter study. I: Dermatologic Therapy. 2017 ; Bind 30, Nr. 6.

Bibtex

@article{ca53a56bcac84802b812d972399fd28e,
title = "Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study",
abstract = "Secukinumab (anti-IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real-life data on effectiveness and safety lack. We aimed to present real-life data of all Danish patients treated with secukinumab (n = 69). At baseline, before initiation of treatment with secukinumab 300 mg (47.8%) or off-label treatment with secukinumab 150 mg (52.2%), the median PASI score was 7.1. A total of 66.7% (34/51) and 52.9% (27/51) of patients still on secukinumab at week 12 achieved a PASI (Psoriasis Area and Severity Index)-50 and PASI-75 of 66.7% and 52.9%, respectively. A total of 83.0% (44/53) and 60.4% (32/53) of the patients had a PASI-score < 5 and PASI-score < 2, respectively, after 12 weeks on treatment with secukinumab. A third of the patients had secukinumab discontinued due to limited clinical improvement or adverse events (n = 23) within a median of 92 days (interquartile range 51-212 days). Notably, the majority of the patients may represent a particularly difficult-to-treat group of patients, as 92.8% had been refractory to other biologic treatment. A total of 26.1% (n = 18) experienced adverse events. Secukinumab appears to be an effective treatment option with a favorable side effect profile in patients with plaque psoriasis who are refractory to or have side effects of traditional biologic drugs.",
keywords = "Journal Article",
author = "Schwensen, {J F} and A Clemmensen and C Sand and R Gniadecki and L Skov and C Zachariae and L Iversen and M Rasmussen and Thomsen, {S F}",
note = "{\textcopyright} 2017 Wiley Periodicals, Inc.",
year = "2017",
month = nov,
doi = "10.1111/dth.12550",
language = "English",
volume = "30",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis

T2 - A retrospective multicenter study

AU - Schwensen, J F

AU - Clemmensen, A

AU - Sand, C

AU - Gniadecki, R

AU - Skov, L

AU - Zachariae, C

AU - Iversen, L

AU - Rasmussen, M

AU - Thomsen, S F

N1 - © 2017 Wiley Periodicals, Inc.

PY - 2017/11

Y1 - 2017/11

N2 - Secukinumab (anti-IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real-life data on effectiveness and safety lack. We aimed to present real-life data of all Danish patients treated with secukinumab (n = 69). At baseline, before initiation of treatment with secukinumab 300 mg (47.8%) or off-label treatment with secukinumab 150 mg (52.2%), the median PASI score was 7.1. A total of 66.7% (34/51) and 52.9% (27/51) of patients still on secukinumab at week 12 achieved a PASI (Psoriasis Area and Severity Index)-50 and PASI-75 of 66.7% and 52.9%, respectively. A total of 83.0% (44/53) and 60.4% (32/53) of the patients had a PASI-score < 5 and PASI-score < 2, respectively, after 12 weeks on treatment with secukinumab. A third of the patients had secukinumab discontinued due to limited clinical improvement or adverse events (n = 23) within a median of 92 days (interquartile range 51-212 days). Notably, the majority of the patients may represent a particularly difficult-to-treat group of patients, as 92.8% had been refractory to other biologic treatment. A total of 26.1% (n = 18) experienced adverse events. Secukinumab appears to be an effective treatment option with a favorable side effect profile in patients with plaque psoriasis who are refractory to or have side effects of traditional biologic drugs.

AB - Secukinumab (anti-IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real-life data on effectiveness and safety lack. We aimed to present real-life data of all Danish patients treated with secukinumab (n = 69). At baseline, before initiation of treatment with secukinumab 300 mg (47.8%) or off-label treatment with secukinumab 150 mg (52.2%), the median PASI score was 7.1. A total of 66.7% (34/51) and 52.9% (27/51) of patients still on secukinumab at week 12 achieved a PASI (Psoriasis Area and Severity Index)-50 and PASI-75 of 66.7% and 52.9%, respectively. A total of 83.0% (44/53) and 60.4% (32/53) of the patients had a PASI-score < 5 and PASI-score < 2, respectively, after 12 weeks on treatment with secukinumab. A third of the patients had secukinumab discontinued due to limited clinical improvement or adverse events (n = 23) within a median of 92 days (interquartile range 51-212 days). Notably, the majority of the patients may represent a particularly difficult-to-treat group of patients, as 92.8% had been refractory to other biologic treatment. A total of 26.1% (n = 18) experienced adverse events. Secukinumab appears to be an effective treatment option with a favorable side effect profile in patients with plaque psoriasis who are refractory to or have side effects of traditional biologic drugs.

KW - Journal Article

U2 - 10.1111/dth.12550

DO - 10.1111/dth.12550

M3 - Letter

C2 - 28906051

VL - 30

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 6

M1 - e12550

ER -

ID: 183469566